Covington & Burling (Brussels)

Jennifer Boudet

Covington & Burling (Brussels)
Lawyer (Associate)

Jennifer Boudet is an associate in the Brussels office. Her practice focuses on all areas of EU Competition law, including cartel investigations, abuse of dominant position cases, state aid cases as well as regulatory issues. Ms. Boudet advises clients in a variety of sectors, including media and technology, energy and natural resources. She did her studies at the University of Paris I - Panthéon - Sorbonne and she hols an LL.M. from the College of Europe.

Auteurs associés

Covington & Burling (Washington)
Covington & Burling (London)
Covington & Burling (Brussels)
Covington & Burling (Washington)
Covington & Burling (Washington)


3815 Bulletin

Jennifer Boudet, Johan Ysewyn Leniency and competition law : An overview of EU and national case law


More than 20 years after the adoption of the first European Commission Leniency Notice, the detection and sanctioning of cartels remains a key feature of the enforcement agenda of the European Commission (the “Commission”) and – the currently still 28 – European Union (“EU”) national competition authorities (“NCAs” or “CAs”). Leniency programmes are a crucial tool in uncovering cartels, with a large majority of cartel decisions adopted by European competition authorities based on immunity and leniency applications. But for how long ?

Miranda Cole, Jennifer Boudet The EU Court of Justice finds that a luxury goods supplier may prevent its authorized retailers from using third-party platforms to sell its products to preserve the products’ luxury image (Coty Germany / Parfümerie Akzente)


On 6 December 2017, the Court of Justice of European Union (CJEU) issued its long-awaited Judgment in Coty Germany GmbH v Parfümerie Akzente GmbH. Taking an approach similar to that adopted by Advocate General (AG) Wahl in his Opinion in July, the CJEU found that a supplier of luxury goods may (...)

201 Revue

Ianis Girgenson, Jennifer Boudet Engagements : La Commission européenne autorise la fusion entre deux fabricants de dispositifs médicaux en dépit de leur leadership sur de nombreux marchés (Johnson & Johnson, Synthes)


Le 18 avril 2012, la Commission européenne a autorisé, sous réserve d’engagements, l’acquisition de Synthes Inc. par Johnson & Johnson (“J&J”). Cette décision, publiée en mai 2013, constitue une victoire majeure pour J&J. En effet, l’opération (valorisée à $19,7 milliards) donnait lieu à des (...)


Envoyer un message